Proteomic Fingerprint of Lung Fibrosis Progression and Response to Therapy in Bleomycin-Induced Mouse Model
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24054410 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Lucrezia Principi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Proteomics and Metabolomics Unit, Department of Medicine and Surgery, University of Milano-Bicocca, 20854 Monza, Italy. Hauptthemen laut MEDLINE: Bleomycin, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FAR 2017-2021, Fondazione Gigi & Pupa Ferrari Onlus, Regione Lombardia.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by the aberrant accumulation of extracellular matrix in the lungs. nintedanib is one of the two FDA-approved drugs for IPF treatment; however, the exact pathophysiological mechanisms of fibrosis progression and response to therapy are still poorly understood. In this work, the molecular fingerprint of fibrosis progression and response to nintedanib treatment have been investigated by mass spectrometry-based bottom-up proteomics in paraffin-embedded lung tissues from bleomycin-induced (BLM) pulmonary fibrosis mice. Our proteomics results unveiled that (i) samples clustered depending on the tissue fibrotic grade (mild, moderate, and severe) and not on the time course after BLM treatment; (ii) the dysregulation of different pathways involved in fibrosis progression such as the complement coagulation cascades, advanced glycation end products (AGEs) and their receptors (RAGEs) signaling, the extracellular matrix-receptor interaction, the regulation of actin cytoskeleton, and ribosomes; (iii) Coronin 1A (Coro1a) as the protein with the highest correlation when evaluating the progression of fibrosis, with an increased expression from mild to severe fibrosis; and (iv) a total of 10 differentially expressed proteins (padj-value ≤ 0.05 and Fold change ≤−1.5 or ≥1.5), whose abundance varied in the base of the severity of fibrosis (mild and moderate), were modulated by the antifibrotic treatment with nintedanib, reverting their trend. Notably, nintedanib significantly restored lactate dehydrogenase B (Ldhb) expression but not lactate dehydrogenase A (Ldha). Notwithstanding the need for further investigations to validate the roles of both Coro1a and Ldhb, our findings provide an extensive proteomic characterization with a strong relationship with histomorphometric measurements. These results unveil some biological processes in pulmonary fibrosis and drug-mediated fibrosis therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Proteomics and Metabolomics Unit, Department of Medicine and Surgery, University of Milano-Bicocca, 20854 Monza, Italy.
- Department of Veterinary Science, University of Parma, 43122 Parma, Italy.
- Experimental Pharmacology & Translational Science Department, Chiesi Farmaceutici S.p.A., 43122 Parma, Italy.
ORCID-Profile: Lucrezia Principi, Roberta Ciccimarra, Lisa Pagani, Clizia Chinello, Andrew Smith, Matteo Zoboli, Francesca Ravanetti, Franco Fabio Stellari, Fulvio Magni, Isabella Piga
Förderung
- FAR 2017-2021
- Fondazione Gigi & Pupa Ferrari Onlus
- Regione Lombardia
- Fondazione Gigi and Pupa Ferrari Onlus
- Regione Lombardia, regional law
- Programma degli interventi per la ripresa economica: sviluppo di nuovi accordi di collaborazione con le università per la Ricerca, l’Innovazione e il Trasferim…
Zitieren
APA
Principi, L., Ferrini, E., Ciccimarra, R., Pagani, L., Chinello, C., Previtali, P., Smith, A., Villetti, G., Zoboli, M., Ravanetti, F., Stellari, F. F., Magni, F., & Piga, I. (2023). Proteomic Fingerprint of Lung Fibrosis Progression and Response to Therapy in Bleomycin-Induced Mouse Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24054410
Vancouver
Principi L, Ferrini E, Ciccimarra R, Pagani L, Chinello C, Previtali P, et al. Proteomic Fingerprint of Lung Fibrosis Progression and Response to Therapy in Bleomycin-Induced Mouse Model. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24054410
BibTeX
@article{Principi2023,
author = {Principi, Lucrezia and Ferrini, Erica and Ciccimarra, Roberta and Pagani, Lisa and Chinello, Clizia and Previtali, Paolo and Smith, Andrew and Villetti, Gino and Zoboli, Matteo and Ravanetti, Francesca and Stellari, Franco Fabio and Magni, Fulvio and Piga, Isabella},
title = {Proteomic Fingerprint of Lung Fibrosis Progression and Response to Therapy in Bleomycin-Induced Mouse Model},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24054410}
}
EUVIMED